Skip to main content
Clinical Trials/NCT05928234
NCT05928234
Recruiting
N/A

A Longterm Follow-up and Comparison of Morbidity and Heart Health Between Patients With Pulmonary Atresia With Intact Ventricular Septum and Uni- or Biventricular Circulation

Vastra Gotaland Region1 site in 1 country140 target enrollmentJuly 15, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pulmonary Atresia With Intact Ventricular Septum
Sponsor
Vastra Gotaland Region
Enrollment
140
Locations
1
Primary Endpoint
Difference in comorbidity between the two groups
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this observational study is to compare patients with pulmonary atresia with intact ventricular septum (PA-IVS) with univentricular circulation to patients with the same heart defect but that has a biventricular circulation in regards to mortality, quality of life, comorbidity, cardiac function, and work capacity. The main questions the study aims to answer are:

• Do mortality, quality of life, comorbidity, cardiac function, and work capacity differ between patients with PA-IVS who have univentricular and biventricular circulation?

Participants will be asked to answer a Quality of Life questionnaire. The investigators will also inquire with a sample size of the research subjects (based on place of residence) about their participation in a series of examinations (ergo-spirometry to assess work capacity, transthoracic echocardiogram, magnetic resonance of the heart and blood sampling to assess cardiac function and cardiac health).

Registry
clinicaltrials.gov
Start Date
July 15, 2024
End Date
January 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Vastra Gotaland Region
Responsible Party
Principal Investigator
Principal Investigator

Stina Manhem

MD

Vastra Gotaland Region

Eligibility Criteria

Inclusion Criteria

  • Individuals born with pulmonary atresia with intact ventricular septum (PA-IVS) who are 15 years or older at the start of the study.
  • Regarding the mortality variable, research subjects who have died after the age of 15 years old will be included.

Exclusion Criteria

  • Individuals born with pulmonary atresia with intact ventricular septum who are younger than 15 years old at the start of the study.

Outcomes

Primary Outcomes

Difference in comorbidity between the two groups

Time Frame: September 2024

Difference in myocardial infarction, heart failure, arrhythmia, stroke, malignancy, autoimmune diseases, infections, atopy, certain liver diseases, and protein-losing enteropathy between the two groups

Secondary Outcomes

  • Difference in physical capacity between the two groups(September 2024)
  • Difference in quality of life between the two groups(September 2024)
  • Difference in mortality between the groups(September 2024)
  • Difference in cardiac capacity between the two groups(September 2024)
  • Difference in general health, linked to cardiac health, between the two groups(September 2024)

Study Sites (1)

Loading locations...

Similar Trials